Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Demeetra AgBio

Main focus: Therapeutic cannabis

Company stage: IND filing

Diseases: Undisclosed

Genome editing tool: Cas-CLOVER

Funding stage: Private

Location: Lexington, KY, USA

Website: https://demeetra.com/

Partners: Poseida Therapeutics, Sanofi

Demeetra Agbio is a privately held agricultural and therapeutic gene-editing company. Based in Kentrucky, US, the company utilises its proprietary Cas-CLOVER platform to genetically modify plants for pharmaceutical use. The Cas-CLOVER system uses two guide RNAs (gRNAs) rather than the conventional single gRNA used in CRISPR-Cas9 editing. Demeetra Agbio's components are licensed to several companies including Sanofi and Poseida Therapeutics.

Tags

HashtagDemeetra AgBio

Company: Demeetra AgBio
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine